Moreover, TIGIT blockers synergistically inhibited carcinoma growth when combined with PD-1 inhibitors, suggesting that elevated expression of TIGIT may promote the progression of hepatocellular carcinoma. This evidence concerns the gene TIGIT and hepatocellular carcinoma.